Background - Data on the presence of subclinical fibrosis across multiple organs in patients with idiopathic lung fibrosis (IPF) are lacking. Our study aimed at investigating through hepatic transient elastography (HTE) the prevalence and clinical impact of subclinical liver fibrosis in a cohort of patients with IPF. Methods - Patients referred to the Centre for Rare Lung Disease of the University Hospital of Modena (Italy) from March 2012 to February 2013with established diagnosis of IPF and without a documented history of liver diseases were consecutively enrolled and underwent HTE. Based on hepatic stiffness status as assessed through METAVIR score patients were categorized as “ with liver fibrosis ” (corresponding to a METAVIR score of F1-F4) and “ without liver fibrosis” (METAVIR F0). Potential predictors of liver fibrosis were investigated through logistic regression model among clinical and serological variables. The overall survival (OS) was assessed according to liver fibrosis and multivariate Cox regression analysis was used to identify independent predictors. Results - In 13 out of 37 patients (35%) with IPF a certain degree of liver fibrosis was documented.No correlation was found between liver stiffness and clinical-functional parameters. OS was lower in patients ‘ with liver fibrosis’ than in patients ‘ without liver fibrosis’ (median months 33[23-55] vs. 63[26-94], p=0.038). Patients ‘ with liver fibrosis’ presented a higher risk of death at seven years as compared to patients ‘without liver fibrosis’ (HR=2.6, 95%CI[1.003–6.7],p= 0.049). Higher level of AST to platelet ratio Index (APRI)was an independent predictor of survival (HR=4.52 95%CI[1.3–15.6], p=0.02). Conclusions - In our cohort, more than one third of IPF patients had concomitant subclinical liver fibrosis that negatively affected OS. These preliminary claims further investigation aimed at clarifying the mechanisms beyond multiorgan fibrosis and its clinical implication in patients with IPF.

Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis / Cocconcelli, E; Tonelli, R; Abbati, G; Marchioni, A; Castaniere, I; Pelizzaro, F; Russo, Fp; Vegetti, A; Balestro, E; Pietrangelo, A; Richeldi, L; Luppi, F; Spagnolo, P; Clini, E; Cerri, S.. - In: INTERNAL AND EMERGENCY MEDICINE. - ISSN 1970-9366. - 16:2(2021), pp. 349-357. [10.1007/s11739-020-02376-2]

Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis

Tonelli, R;Marchioni, A;Castaniere, I;Pietrangelo, A;Clini, E;Cerri, S.
2021

Abstract

Background - Data on the presence of subclinical fibrosis across multiple organs in patients with idiopathic lung fibrosis (IPF) are lacking. Our study aimed at investigating through hepatic transient elastography (HTE) the prevalence and clinical impact of subclinical liver fibrosis in a cohort of patients with IPF. Methods - Patients referred to the Centre for Rare Lung Disease of the University Hospital of Modena (Italy) from March 2012 to February 2013with established diagnosis of IPF and without a documented history of liver diseases were consecutively enrolled and underwent HTE. Based on hepatic stiffness status as assessed through METAVIR score patients were categorized as “ with liver fibrosis ” (corresponding to a METAVIR score of F1-F4) and “ without liver fibrosis” (METAVIR F0). Potential predictors of liver fibrosis were investigated through logistic regression model among clinical and serological variables. The overall survival (OS) was assessed according to liver fibrosis and multivariate Cox regression analysis was used to identify independent predictors. Results - In 13 out of 37 patients (35%) with IPF a certain degree of liver fibrosis was documented.No correlation was found between liver stiffness and clinical-functional parameters. OS was lower in patients ‘ with liver fibrosis’ than in patients ‘ without liver fibrosis’ (median months 33[23-55] vs. 63[26-94], p=0.038). Patients ‘ with liver fibrosis’ presented a higher risk of death at seven years as compared to patients ‘without liver fibrosis’ (HR=2.6, 95%CI[1.003–6.7],p= 0.049). Higher level of AST to platelet ratio Index (APRI)was an independent predictor of survival (HR=4.52 95%CI[1.3–15.6], p=0.02). Conclusions - In our cohort, more than one third of IPF patients had concomitant subclinical liver fibrosis that negatively affected OS. These preliminary claims further investigation aimed at clarifying the mechanisms beyond multiorgan fibrosis and its clinical implication in patients with IPF.
2021
25-mag-2020
16
2
349
357
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis / Cocconcelli, E; Tonelli, R; Abbati, G; Marchioni, A; Castaniere, I; Pelizzaro, F; Russo, Fp; Vegetti, A; Balestro, E; Pietrangelo, A; Richeldi, L; Luppi, F; Spagnolo, P; Clini, E; Cerri, S.. - In: INTERNAL AND EMERGENCY MEDICINE. - ISSN 1970-9366. - 16:2(2021), pp. 349-357. [10.1007/s11739-020-02376-2]
Cocconcelli, E; Tonelli, R; Abbati, G; Marchioni, A; Castaniere, I; Pelizzaro, F; Russo, Fp; Vegetti, A; Balestro, E; Pietrangelo, A; Richeldi, L; Lup...espandi
File in questo prodotto:
File Dimensione Formato  
IAEM-S-20-00231.pdf

Open access

Tipologia: Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione 3.61 MB
Formato Adobe PDF
3.61 MB Adobe PDF Visualizza/Apri
s11739-020-02376-2.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 688.36 kB
Formato Adobe PDF
688.36 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1203295
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 8
social impact